Clinical Research Directory
Browse clinical research sites, groups, and studies.
Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
Sponsor: Chinese PLA General Hospital
Summary
The study is to observe safety, survival effect and peripheral T-lymphocyte subsets of combination therapy with percutaneous microwave ablation (MWA) and adoptive immunotherapy in hepatocellular carcinoma(HCC).
Official title: Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2009-12
Completion Date
2028-12-31
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
adoptive immunotherapy
Patients with HCC (tumor diameter ≤5 cm and fewer than three tumors) underwent radical MWA followed by cellular immunotherapy. In the CIK-based cohort, patients received 4-6 courses annually, starting at 2, 4, 6, 10, 14, and 18 weeks after MWA, followed by treatment every 12 weeks. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were administered intraperitoneally, and CIK cells were infused intravenously. In the NK-cell cohort, patients received six NK-cell infusions at 2-week intervals after complete MWA and normalization of body temperature. NK cells were expanded ex vivo from autologous peripheral blood, allogeneic peripheral blood, or umbilical cord blood.
MWA
ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
Locations (1)
Chinese PLA General Hospital
Beijing, Beijing Municipality, China